Bryan Truman Hunt
Insider
First SEC filing: Jan. 11, 2021 · Latest: Jan. 11, 2021
Insider at
Insider transactions
0 buys (P)
0 sells (S)
Net: $0
Price change vs current quote, split-adjusted for corporate actions since the filing — not benchmarked, not annualized, not size-weighted
| Date | Ticker | Code | Shares | Price | Value | Owned after | Δ own | A/D | vs now |
|---|---|---|---|---|---|---|---|---|---|
| March 1, 2024 | HCAT | F | 11,684 | $8.05 | $94,056 | 219,849 Direct | -5.05% | Disposed | -78.0% (price as of 2026-10-06) |
| Feb. 20, 2024 | HCAT | A | 11,111 | · | · | 231,533 Direct | +5.04% | Acquired | (price as of 2026-10-06) |
| Dec. 1, 2023 | HCAT | F | 14,118 | $7.45 | $105,179 | 220,422 Direct | -6.02% | Disposed | -76.2% (price as of 2026-10-06) |
| Sept. 1, 2023 | HCAT | F | 4,128 | $11.78 | $48,628 | 234,540 Direct | -1.73% | Disposed | -85.0% (price as of 2026-10-06) |
| June 5, 2023 | HCAT | S 10b5-1 | 650 | $12.00 | $7,800 | 238,668 Direct | -0.27% | Disposed | -85.3% (price as of 2026-10-06) |
| June 1, 2023 | HCAT | F | 4,433 | $11.24 | $49,827 | 239,318 Direct | -1.82% | Disposed | -84.3% (price as of 2026-10-06) |
| March 3, 2023 | HCAT | S 10b5-1 | 760 | $14.34 | $10,898 | 232,826 Direct | -0.33% | Disposed | -87.7% (price as of 2026-10-06) |
| March 1, 2023 | HCAT | F | 3,351 | $14.29 | $47,886 | 233,586 Direct | -1.41% | Disposed | -87.6% (price as of 2026-10-06) |
| Feb. 22, 2023 | HCAT | A | 100,000 | · | · | 236,937 Direct | +73.03% | Acquired | (price as of 2026-10-06) |
| Jan. 18, 2023 | HCAT | S 10b5-1 | 2,354 | $12.53 | $29,496 | 136,937 Direct | -1.69% | Disposed | -85.9% (price as of 2026-10-06) |
| Jan. 17, 2023 | HCAT | S 10b5-1 | 2,055 | $12.00 | $24,660 | 139,291 Direct | -1.45% | Disposed | -85.3% (price as of 2026-10-06) |
| Dec. 1, 2022 | HCAT | F | 9,129 | $10.65 | $97,224 | 141,346 Direct | -6.07% | Disposed | -83.4% (price as of 2026-10-06) |
| Sept. 1, 2022 | HCAT | F | 1,414 | $11.60 | $16,402 | 150,475 Direct | -0.93% | Disposed | -84.7% (price as of 2026-10-06) |
| June 1, 2022 | HCAT | F | 4,523 | $14.24 | $64,408 | 152,053 Direct | -2.89% | Disposed | -87.6% (price as of 2026-10-06) |
| June 1, 2022 | HCAT | F | 164 | $14.95 | $2,452 | 151,889 Direct | -0.11% | Disposed | -88.2% (price as of 2026-10-06) |
| March 2, 2022 | HCAT | F | 302 | $26.69 | $8,060 | 156,576 Direct | -0.19% | Disposed | -93.4% (price as of 2026-10-06) |
| March 1, 2022 | HCAT | F | 1,856 | $26.63 | $49,425 | 154,458 Direct | -1.19% | Disposed | -93.4% (price as of 2026-10-06) |
| March 1, 2022 | HCAT | A | 2,420 | · | · | 156,878 Direct | +1.57% | Acquired | (price as of 2026-10-06) |
| Feb. 24, 2022 | HCAT | A | 100,000 | · | · | 156,314 Direct | +177.58% | Acquired | (price as of 2026-10-06) |
| Dec. 2, 2021 | HCAT | F | 4,960 | $41.95 | $208,072 | 56,314 Direct | -8.09% | Disposed | -95.8% (price as of 2026-10-06) |
| Nov. 12, 2021 | HCAT | S 10b5-1 | 957 | $49.40 | $47,276 | 61,274 Direct | -1.54% | Disposed | -96.4% (price as of 2026-10-06) |
| Sept. 1, 2021 | HCAT | F | 286 | $54.23 | $15,510 | 62,231 Direct | -0.46% | Disposed | -96.7% (price as of 2026-10-06) |
| June 1, 2021 | HCAT | F | 272 | $53.88 | $14,655 | 62,517 Direct | -0.43% | Disposed | -96.7% (price as of 2026-10-06) |
| March 1, 2021 | HCAT | F | 326 | $48.60 | $15,844 | 62,799 Direct | -0.52% | Disposed | -96.4% (price as of 2026-10-06) |
| March 1, 2021 | HCAT | F | 10 | $49.63 | $496 | 62,789 Direct | -0.02% | Disposed | -96.4% (price as of 2026-10-06) |
| Feb. 18, 2021 | HCAT | A | 60,000 | · | · | 63,125 Direct | +1920.00% | Acquired | (price as of 2026-10-06) |
P = Open-market purchase · S = Sale · A = Grant/award · M = Option exercise · G = Gift · F = Tax withholding
Insider transactions are not a recommendation; sales are often driven by liquidity or tax reasons.
Initial ownership (Form 3) 6 holdings
Securities held when first becoming an insider, per SEC Form 3.
| Date | Ticker | Security | Shares | Ownership |
|---|---|---|---|---|
| Jan. 11, 2021 | HCAT | Common Stock | 7,653 | Direct |
| Jan. 11, 2021 | HCAT | Common Stock | 3,125 | Direct |
| Jan. 11, 2021 | HCAT | Stock Options (Right to buy) | 12,500 | Direct |
| Jan. 11, 2021 | HCAT | Stock Options (Right to buy) | 4,150 | Direct |
| Jan. 11, 2021 | HCAT | Stock Options (Right to buy) | 2,188 | Direct |
| Jan. 11, 2021 | HCAT | Stock Options (Right to buy) | 261 | Direct |
Compensation (DEF 14A)
Matched by name from proxy statements (DEF 14A) — verify against the filing.
| Fiscal year | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension change | Other | Total |
|---|---|---|---|---|---|---|---|---|
| 2024 | $83,750 | · | · | · | · | · | $714,705 | $798,455 |
| 2023 | $315,000 | · | $1,980,055 | · | $56,579 | · | $33,676 | $2,385,310 |
| 2022 | $300,000 | · | $2,816,993 | · | $59,681 | · | $10,783 | $3,187,457 |
Figures from the Summary Compensation Table of the company's proxy statement (DEF 14A). Compensation is not a recommendation.